An interventional study of Iron Bioresorbable Scaffold System (IBS Angel) in Pulmonary Artery Stenosis, sponsored by Biotyx Medical (Shenzhen) Co., Ltd.. Recruiting at 10 sites in China. Open to participants aged 1 Year to 14 Years. Per ClinicalTrials.gov, last updated 2021-11-19.
Sponsored by Biotyx Medical (Shenzhen) Co., Ltd. (part of LifeTech Scientific Corporation) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a prospective, multi-center, single-arm clinical trial to evaluate the safety and efficacy of Iron Bioresorbable Scaffold System (IBS Angel) in patients with pulmonary artery stenosis.
82 patients with pulmonary artery stenosis will be treated with the Iron Bioresorbable Scaffold System (IBS Angel) developed by Biotyx Medical (Shenzhen) Co., Ltd. This study is designed as a prospective, multi-center, single-arm clinical trial. Enrolled patients will undergo IBS Angel implantation and will be followed up at 1, 3, 6, 12, and 24 months post-procedure.
Biotyx Medical (Shenzhen) Co., Ltd. is the lead sponsor of 6 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients who have congenital or secondary pulmonary artery stenosis (including pulmonary artery trunk, left pulmonary artery and right pulmonary artery), and meeting one of the following criteria:
A: The pressure gradient across the stenosis ≥20mmHg measured by catheter; B: The degree of pulmonary artery stenosis ≥50% ( calculated by (diameter of adjacent normal segments - residual lumen diameter of the stenosis segment)/diameter of adjacent normal segments ×100%); C: The ratio of right ventricular systolic pressure to aortic systolic pressure ≥50%.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Iron Bioresorbable Scaffold System
Device: Iron Bioresorbable Scaffold System (IBS Angel)
Subjects in this arm will be implanted with IBS Angel.
Rate of freedom from in-stent restenosis
Defined on a per target lesion basis.
Time frame: 12 months
Rate of procedural success
Defined on a per target lesion basis.
Time frame: Immediately post-procedure
Rate of technical success
Defined on a per target lesion basis.
Time frame: Immediately post-procedure
Rate of freedom from in-stent restenosis
Defined on a per target lesion basis.
Time frame: 1 month
Rate of freedom from in-stent restenosis
Defined on a per target lesion basis.
Time frame: 3 months
Rate of freedom from in-stent restenosis
Defined on a per target lesion basis.
Time frame: 6 months
Rate of device-related adverse events
Time frame: 1 month
Rate of device-related serious adverse events
Time frame: 1 month
Rate of device-related adverse events
Time frame: 3 months
Rate of device-related serious adverse events
Time frame: 3 months
Rate of device-related adverse events
Time frame: 6 months
Rate of device-related serious adverse events
Time frame: 6 months
Rate of device-related adverse events
Time frame: 12 months
Rate of device-related serious adverse events
Time frame: 12 months
Rate of device-related adverse events
Time frame: 24 months
Rate of device-related serious adverse events
Time frame: 24 months
Rate of unplanned surgery or re-intervention
Time frame: 1 month
Rate of unplanned surgery or re-intervention
Time frame: 3 months
Rate of unplanned surgery or re-intervention
Time frame: 6 months
Rate of unplanned surgery or re-intervention
Time frame: 12 months
Rate of unplanned surgery or re-intervention
Time frame: 24 months
Rate of stent thrombosis
Time frame: 1 month
Rate of stent thrombosis
Time frame: 3 months
Rate of stent thrombosis
Time frame: 6 months
Rate of stent thrombosis
Time frame: 12 months
Rate of stent thrombosis
Time frame: 24 months
Rate of all-cause death
Time frame: 1 month
Rate of all-cause death
Time frame: 3 months
Rate of all-cause death
Time frame: 6 months
Rate of all-cause death
Time frame: 12 months
Rate of all-cause death
Time frame: 24 months
Rate of stent displacement
Time frame: 1 month
Rate of stent displacement
Time frame: 3 months
Rate of stent displacement
Time frame: 6 months
Rate of stent displacement
Time frame: 12 months
Rate of adverse events
Time frame: 1 month
Rate of serious adverse events
Time frame: 1 month
Rate of adverse events
Time frame: 3 months
Rate of serious adverse events
Time frame: 3 months
Rate of adverse events
Time frame: 6 months
Rate of serious adverse events
Time frame: 6 months
Rate of adverse events
Time frame: 12 months
Rate of serious adverse events
Time frame: 12 months
Rate of adverse events
Time frame: 24 months
Rate of serious adverse events
Time frame: 24 months
Rate of device deficiency
Time frame: Day 0
Started Jul 2021 (actual). Primary completion is estimated for Jul 2024, 36 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Stenosis, Pulmonary Artery
Biotyx Medical (Shenzhen) Co., Ltd. →